Literature DB >> 15990996

[Recent insights into Rasmussen encephalitis].

C G Bien1, C E Elger.   

Abstract

Rasmussen encephalitis (RE) is a severe and at the same time pathophysiologically fascinating condition. The chronic inflammation affects one of the two cerebral hemispheres and destroys it during the disease process that lasts from months to years. The patients -- mostly children -- suffer from frequent pharmacoresistant seizures, often in the form of epilepsia partialis continua. In parallel to the atrophy of the affected hemisphere, the neurological functions associated with it decline continuously. This results in a final stage with a usually high-grade sensorimotor hemisyndrome, hemianopia, cognitive impairment and -- if the language-dominant hemisphere is affected -- aphasia. Research results in the last 5 years have contributed to a deeper understanding of the pathogenesis of this condition. Formal diagnostic criteria have been proposed, and new therapeutic options have emerged by which the disease progression can be slowed or stopped. This article summarizes the current research results on the background of older data and gives recommendations regarding diagnostic and therapeutic procedures in RE patients.

Entities:  

Mesh:

Year:  2005        PMID: 15990996     DOI: 10.1007/s00115-005-1955-0

Source DB:  PubMed          Journal:  Nervenarzt        ISSN: 0028-2804            Impact factor:   1.214


  77 in total

1.  Chronic encephalitis and epilepsy in adults and adolescents: a variant of Rasmussen's syndrome?

Authors:  Y M Hart; F Andermann; D R Fish; F Dubeau; Y Robitaille; T Rasmussen; S Berkovic; R Marino; E M Yakoubian; K Spillane; F Scaravilli
Journal:  Neurology       Date:  1997-02       Impact factor: 9.910

2.  Treatment of Rasmussen's syndrome with ganciclovir.

Authors:  R S McLachlan; S Levin; W T Blume
Journal:  Neurology       Date:  1996-10       Impact factor: 9.910

3.  Diagnostic imaging in 13 cases of Rasmussen's encephalitis: can early MRI suggest the diagnosis?

Authors:  L Chiapparini; T Granata; L Farina; E Ciceri; A Erbetta; F Ragona; E Freri; L Fusco; G Gobbi; G Capovilla; L Tassi; L Giordano; M Viri; B Dalla Bernardina; R Spreafico; M Savoiardo
Journal:  Neuroradiology       Date:  2003-02-12       Impact factor: 2.804

Review 4.  Autoimmunity and neurological disease: antibody modulation of synaptic transmission.

Authors:  K D Whitney; J O McNamara
Journal:  Annu Rev Neurosci       Date:  1999       Impact factor: 12.449

5.  Glutamate receptor GluR3 antibodies and death of cortical cells.

Authors:  X P He; M Patel; K D Whitney; S Janumpalli; A Tenner; J O McNamara
Journal:  Neuron       Date:  1998-01       Impact factor: 17.173

6.  Autoantibodies to glutamate receptor GluR3 in Rasmussen's encephalitis.

Authors:  S W Rogers; P I Andrews; L C Gahring; T Whisenand; K Cauley; B Crain; T E Hughes; S F Heinemann; J O McNamara
Journal:  Science       Date:  1994-07-29       Impact factor: 47.728

7.  Medical treatment of Rasmussen's syndrome (chronic encephalitis and epilepsy): effect of high-dose steroids or immunoglobulins in 19 patients.

Authors:  Y M Hart; M Cortez; F Andermann; P Hwang; D R Fish; O Dulac; K Silver; N Fejerman; H Cross; A Sherwin
Journal:  Neurology       Date:  1994-06       Impact factor: 9.910

8.  Chronic focal encephalitis (Rasmussen syndrome): six cases.

Authors:  J H Piatt; P A Hwang; D C Armstrong; L E Becker; H J Hoffman
Journal:  Epilepsia       Date:  1988 May-Jun       Impact factor: 5.864

9.  Rasmussen's chronic encephalitis in adults.

Authors:  R S McLachlan; J P Girvin; W T Blume; H Reichman
Journal:  Arch Neurol       Date:  1993-03

10.  Rasmussen encephalitis with active inflammation and delayed seizures onset.

Authors:  I Korn-Lubetzki; C G Bien; J Bauer; M Gomori; H Wiendl; L Trajo; H Ovadia; B Wilken; V H Hans; C E Elger; H Hurvitz; I Steiner
Journal:  Neurology       Date:  2004-03-23       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.